{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:50:51Z","timestamp":1790351451611,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>To evaluate whether molecular classification was associated with treatment response and recurrence in women with atypical endometrial hyperplasia (AEH) or early-stage endometrial cancer (EC) treated with progestin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis of 116 patients (71 AEH and 45 EC) who received fertility-sparing therapy between 2010 and 2022 was performed. Tumors were classified via immunohistochemistry and gene sequencing into four subgroups: polymerase-\u03f5 (POLE)-mutated (POLEmut), tumor protein 53 (p53) wild type [p53wt; no specific molecular profile (NSMP)], mismatch repair deficient (MMRd), and p53 abnormal (p53abn). The primary outcome was complete response (CR) to hormone therapy. The secondary outcomes included the recurrence rate after CR and conception success. The treatment response to progestin and recurrence rate were compared across the four subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 116 patients, 10 (8.62%) were classified as POLEmut, 81 (69.82%) p53wt, 9 (7.76%) p53abn, and 16 (13.76%) MMRd. At the 12-month evaluation, 87 patients (75.00%) achieved CR (median treatment duration, 5.95 months; range, 1.6\u201312.9). Partial response (PR), stable disease (SD), and progressive disease (PD) rates were 6.89% (n = 8), 1.72% (n = 2), and 16.38% (n = 19), respectively. Patients with the p53abn and MMRd subtypes had lower CR rates (33.33% and 37.50%) and higher progression rates (44.40% and 37.50%) compared to other subgroups (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). After 24-month follow-up, recurrence rates were markedly higher in the p53abn (100%) and MMRd (83.33%) subgroups versus the POLEmut (33.33%) and p53wt (17.39%) subgroups (<jats:italic>p<\/jats:italic> &amp;lt; 0.05). Among 56 (64.37%) patients attempting conception, the pregnancy rate of 38 patients who received <jats:italic>in vitro<\/jats:italic> fertilization-embryo transfer was 47.37% (18\/38), and the pregnancy rate of 18 patients who chose natural pregnancy was 16.67% (3\/18), showing no statistical difference (<jats:italic>p<\/jats:italic> = 0.072).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Molecular classification may be associated with hormone treatment response in patients with AEH, EC patients with POLEmut and p53wt had better progestin response, and those with MMRd and p53abn had the poorest response and the highest recurrence rate. Recurrence was common after CR, but close review is necessary. For further investigation of the role of molecular classification in fertility-sparing treatment of AEH\/EC, larger prospective studies are necessary.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1506639","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T04:11:24Z","timestamp":1744690284000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["The association of molecular classification with fertility-sparing treatment of atypical endometrial hyperplasia and endometrial cancer: a retrospective study"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuanyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjiao","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danxia","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004989","article-title":"Endometrial hyperplasia","volume":"140","author":"Ring","year":"2022","journal-title":"Obstetrics Gynecol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14081922","article-title":"Endometrial cancer management in young women","volume":"14","author":"Markowska","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850715)56:2<403::aid-cncr2820560233>3.0.co;2-x","article-title":"The behavior of endometrial hyperplasia. A long-term study of \u201cuntreated\u201d hyperplasia in 170 patients","volume":"56","author":"Kurman","year":"1985","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4070368","article-title":"Fertility-sparing approach in patients with endometrioid endometrial cancer grade 2 stage IA (FIGO): A qualitative systematic review","volume":"2022","author":"Giampaolino","year":"2022","journal-title":"BioMed Res Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/hropen\/hoac057","article-title":"ESGO\/ESHRE\/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","volume":"2023","author":"Rodolakis","year":"2023","journal-title":"Hum Reprod Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20201014\u201300897","article-title":"Clinical outcomes analysis of fertility-preserving therapy for atypical endometrial hyperplasia and early endometrial carcinoma","volume":"44","author":"He","year":"2022","journal-title":"Chin J Reprod Contracep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-021-06375-2","article-title":"Fertility sparing treatment in patients with endometrial cancer (FERT-ENC): a multicentric retrospective study from the Spanish Investigational Network Gynecologic Oncology Group (SPAIN-GOG)","volume":"306","author":"Lago","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"370.e1","DOI":"10.1016\/j.ajog.2020.10.003","article-title":"Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer","volume":"224","author":"Chung","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.22","article-title":"Increased proliferation in atypical hyperplasia\/endometrioid intraepithelial neoplasia of the endometrium with concurrent inactivation of ARID1A and PTEN tumour suppressors","volume":"1","author":"Ayhan","year":"2015","journal-title":"J Pathol Clin Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.82","article-title":"Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification","volume":"3","author":"Karnezis","year":"2017","journal-title":"J Pathol Clin Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-019-05145-5","article-title":"Molecular expression characteristics confirm the Malignancy concealed by morphological alterations in endometrial cancer after fertility-preserving treatment","volume":"299","author":"Hu","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2019.07.013","article-title":"Application of the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) to patients conservatively treated: Outcomes from an institutional series","volume":"240","author":"Falcone","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2019-000871","article-title":"Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments","volume":"30","author":"Beinse","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.11.006","article-title":"Molecular subtyping in endometrial cancer: A promising strategy to guide fertility preservation","volume":"179","author":"Dagher","year":"2023","journal-title":"Gynecol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2021-002705","article-title":"Incorporating molecular profiling into endometrial cancer management requires prospective studies","volume":"31","author":"Amant","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30496","article-title":"Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer","volume":"123","author":"Talhouk","year":"2017","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.11.007","article-title":"Continued medical treatment for persistent early endometrial cancer in young women","volume":"160","author":"Cho","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123571","article-title":"Fertility sparing treatment of endometrial cancer with and without initial infiltration of myometrium: A single center experience","volume":"12","author":"Casadio","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.11.043","article-title":"Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature","volume":"125","author":"Baker","year":"2012","journal-title":"Gynecol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001328","article-title":"Fertility preservation in women with early-stage gynecologic cancer: optimizing oncologic and reproductive outcomes","volume":"31","author":"Floyd","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3109\/01443615.2010.532249","article-title":"Conservative management of young patients with endometrial highly-differentiated adenocarcinoma","volume":"31","author":"Kalogiannidis","year":"2011","journal-title":"J Obstet Gynaecol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgm052","article-title":"PTEN, more than the AKT pathway","volume":"28","author":"Blanco-Aparicio","year":"2007","journal-title":"Carcinogenesis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101458","article-title":"PTEN and gynecological cancers","volume":"11","author":"Nero","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e27","article-title":"Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia","volume":"35","author":"Lv","year":"2024","journal-title":"J Gynecol Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1282356","article-title":"Outcomes of fertility preservation treatments in patients with endometrial cancer with different molecular classifications based on an NGS panel","volume":"13","author":"Xu","year":"2023","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112847","article-title":"Molecular classification to prognosticate response in medically managed endometrial cancers and endometrial intraepithelial neoplasia","volume":"13","author":"Puechl","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.ygyno.2021.03.029","article-title":"Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study","volume":"161","author":"Raffone","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.14491","article-title":"Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series","volume":"124","author":"Zakhour","year":"2017","journal-title":"BJOG"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.04.013","article-title":"Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment","volume":"186","author":"Peng","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2021.06.007","article-title":"The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review","volume":"263","author":"Piatek","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005297","article-title":"Management of endometrial intraepithelial neoplasia or atypical endometrial hyperplasia: ACOG clinical consensus no. 5","volume":"142","author":"Lori Boardman","year":"2023","journal-title":"Obstet Gynecol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0000000000000493","article-title":"European society of gynecological oncology task force for fertility preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients","volume":"25","author":"Rodolakis","year":"2015","journal-title":"Int J Gynecol Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.04.017","article-title":"Updates on conservative management of endometrial cancer in patients younger than 45 years","volume":"161","author":"Lucchini","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1391546","article-title":"Comparative effects of progestin-based combination therapy for endometrial cancer or atypical endometrial hyperplasia: a\u00a0systematic review and network meta-analysis","volume":"14","author":"Cui","year":"2024","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.16108","article-title":"Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial","volume":"127","author":"Yang","year":"2020","journal-title":"BJOG"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e90","article-title":"Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients","volume":"30","author":"Mitsuhashi","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.03.098","article-title":"Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma","volume":"153","author":"Britton","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/path.5373","article-title":"Clinicopathological and molecular characterisation of \u2018multiple-classifier\u2019 endometrial carcinomas","volume":"250","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J Pathol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.10.012","article-title":"Molecular classification in fertility-sparing treatment of early-stage endometrial cancer: A potential tool for optimizing patient selection","volume":"191","author":"Peng","year":"2024","journal-title":"Gynecol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1506639\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T04:11:27Z","timestamp":1744690287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1506639\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":41,"alternative-id":["10.3389\/fonc.2025.1506639"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1506639","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"article-number":"1506639"}}